AGM
ACHN

Alpine Global Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Alpine Global Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-205,172
Closed -$326K – 253
2018
Q4 		$326K Buy
+205,172
New +$580K 0.08% 125

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alpine Global Management's ACHN Position: Q1 2019 in Review

Alpine Global Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2019, closing a stake of 205,172 shares — an estimated $326K sold.

Alpine Global Management first reported a position in ACHN in Q4 2018 and held it in 1 quarter. The position peaked at $326K in Q4 2018. 110 funds tracked by Wall St. Rank hold ACHN as of Q1 2019.

  • Alpine Global Management reported no remaining Achillion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Alpine Global Management sold 205,172 Achillion Pharmaceuticals shares in Q1 2019, an estimated $326K.
  • Alpine Global Management first reported a position in Achillion Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Alpine Global Management's Achillion Pharmaceuticals position peaked at $326K in Q4 2018.
  • 110 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2019.

Based on Alpine Global Management's 13F filing for Q1 2019, filed 10 May 2019.